- Home
- DAWN vs PDM Comparison
DAWN vs PDM Comparison
Compare DAWN & PDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- PDM
- Stock Information
- Founded
- DAWN 2018
- PDM 1997
- Country
- DAWN United States
- PDM United States
- Employees
- DAWN N/A
- PDM N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- PDM Building operators
- Sector
- DAWN Health Care
- PDM Real Estate
- Exchange
- DAWN Nasdaq
- PDM Nasdaq
- Market Cap
- DAWN 1.2B
- PDM N/A
- IPO Year
- DAWN 2021
- PDM N/A
- Fundamental
- Price
- DAWN $8.07
- PDM $7.23
- Analyst Decision
- DAWN Strong Buy
- PDM Buy
- Analyst Count
- DAWN 7
- PDM 4
- Target Price
- DAWN $32.29
- PDM $10.00
- AVG Volume (30 Days)
- DAWN 1.3M
- PDM 718.1K
- Earning Date
- DAWN 05-05-2025
- PDM 04-29-2025
- Dividend Yield
- DAWN N/A
- PDM 6.94%
- EPS Growth
- DAWN N/A
- PDM N/A
- EPS
- DAWN N/A
- PDM N/A
- Revenue
- DAWN $131,161,000.00
- PDM $570,324,000.00
- Revenue This Year
- DAWN $28.72
- PDM N/A
- Revenue Next Year
- DAWN $73.78
- PDM N/A
- P/E Ratio
- DAWN N/A
- PDM N/A
- Revenue Growth
- DAWN N/A
- PDM N/A
- 52 Week Low
- DAWN $7.88
- PDM $6.27
- 52 Week High
- DAWN $18.07
- PDM $11.12
- Technical
- Relative Strength Index (RSI)
- DAWN 36.05
- PDM 43.08
- Support Level
- DAWN $7.93
- PDM $7.29
- Resistance Level
- DAWN $8.44
- PDM $7.46
- Average True Range (ATR)
- DAWN 0.44
- PDM 0.21
- MACD
- DAWN 0.09
- PDM 0.05
- Stochastic Oscillator
- DAWN 17.59
- PDM 61.02
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.